Physiologically Speaking
MARCH 28, 2025
Greetings! Welcome to the Physiology Friday newsletter. Details about the sponsors of this newsletter including FSTFUEL electrolytes, Examine.com , and my book “VO2 Max Essentials ” can be found at the end of the post. You can find more products I’m affiliated with on my website. Physiologically Speaking is a reader-supported publication.
Open Heart
MARCH 28, 2025
Background The significance of stress-test induced arrhythmias has been examined in prior studies, but there is no clear consensus regarding its significance. Objectives To determine the significance of stress test-induced arrhythmias. Methods Relevant studies examining arrhythmia in both exercise and pharmacological stress testing were searched for in PubMed, Embase and Cochrane databases from inception to 14 June 2023.
Physiologically Speaking
MARCH 21, 2025
Greetings! Welcome to the Physiology Friday newsletter. Details about the sponsors of this newsletter including FSTFUEL electrolytes, Examine.com , and my book “VO2 Max Essentials ” can be found at the end of the post. You can find more products I’m affiliated with on my website. Physiologically Speaking is a reader-supported publication.
Frontiers in Cardiovascular Medicine
MARCH 28, 2025
ST-elevation myocardial infarction (STEMI) is a critical cardiovascular emergency characterized by acute coronary artery occlusion and subsequent myocardial injury. The current standard of care is primary percutaneous coronary intervention (PPCI), which aims to rapidly restore epicardial blood flow. However, despite successful revascularization, microvascular obstruction (MVO) remains a major challenge, contributing to adverse clinical outcomes.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Heart BMJ
MARCH 26, 2025
Background Heart failure with preserved ejection fraction is a recognised outcome in patients with myocardial infarction, although heart failure with reduced ejection fraction is more common. Identifying early indicators specific to heart failure with preserved ejection fraction in patients with myocardial infarction could support targeted preventive strategies.
HCPLive
MARCH 28, 2025
Experts discuss the long-term efficacy and safety of abrocitinib and upadacitinib in atopic dermatitis (AD), with sustained monotherapy results showing significant improvements in Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI), and Validated IGA-AD (vIGA-AD) scores. They also consider the safety profiles and potential risks, particularly in older patients, for long-term use of JAK inhibitors.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
Frontiers in Cardiovascular Medicine
MARCH 28, 2025
IntroductionHeart failure (HF) causes high symptom burden and shortens life expectancy. Implementation of Palliative Care (PC) concurrently with cardiologic guidelines-directed medical therapy (GDMT) improves quality-of-life (QoL) more than disease-oriented management alone but is underused. To facilitate provision of PC for people living with HF, the Swiss Society of Cardiology (SSC) and the Swiss Society for Palliative Care (palliative.ch) have created joint working-group.MethodsDyads represen
Heart BMJ
MARCH 26, 2025
Background Pericardial complications following cardiac surgery are common and debilitating, significantly impacting patients’ survival. We performed this network meta-analysis to identify the most effective and safest preventions and treatments for pericardial complications following cardiac surgery. Methods We systematically searched PubMed/MEDLINE, EMBASE and Cochrane CENTRAL from inception to 22 January 2024.
HCPLive
MARCH 27, 2025
Panelists discuss how selecting among the numerous approved biologic therapies for psoriasis requires a personalized approach that weighs factors such as efficacy data, safety profiles, comorbidities, insurance coverage, and administration preferences, with patient preferences playing a crucial role in the decision-making process, as involving patients in treatment selection enhances medication adherence and satisfaction and ultimately improves long-term outcomes.
CardiacWire
MARCH 26, 2025
New results from a vast Mayo Clinic meta-analysis suggest that combining ezetimibe with statins to lower LDL-C could have significant mortality and MACE benefits over statin monotherapy. Statins are one of the most prescribed drugs in the U.S., with over 25% of all adults 40 and up taking them. However, not everyone with high cholesterol benefits from statins, leading many drug developers to focus on novel ways to lower LDL-C levels.
Open Heart
MARCH 22, 2025
Background Mechanical stress on the heart is commonly considered the sole stimulus explaining the synthesis and release of circulating natriuretic peptides and their derivatives. While one of the most critical paradigms in cardiology is that mechanical load increases oxygen consumption, clinical studies on these peptides have neglected the relationship between mechanical stress and oxygen metabolism.
Frontiers in Cardiovascular Medicine
MARCH 28, 2025
BackgroundThere is a growing body of evidence indicating that metabolites are associated with an increased risk of cardiovascular diseases (CVDs), the underlying causality of these associations remains largely unchallenged. Given the inherent difficulty in establishing causality using epidemiological data, we employed the technique of Mendelian randomization to investigate the potential role of plasma metabolite factors in influencing the risk of CVDs.MethodsThe exposure was based on 1,400 plasm
Heart BMJ
MARCH 26, 2025
Heart failure (HF) is a complex syndrome which leads to significant morbidity and mortality, poor quality of life and extremely high costs to healthcare systems worldwide. Although progress in the management of HF in high-income countries is leading to an overall reduction in the incidence and mortality of HF, there is a starkly different scenario in low- and middle-income countries (LMICs).
HCPLive
MARCH 27, 2025
Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors represent a promising new therapeutic class for chronic spontaneous urticaria (CSU) by offering rapid symptom control through targeted inhibition of both mast cell and B cell pathways, with newer agents like remibrutinib showing high selectivity, favorable safety, and robust efficacy in clinical trials that could position them as an important oral therapy option between antihistamines and biologics.
CardiacWire
MARCH 21, 2025
Its not surprising that Alnylams Amvuttra (vutrisiran) received FDA approval for ATTR-CM last week, but what shocked many was Alnylams choice to price the drug at nearly half a million dollars per year in a segment where its incumbent competitors cost half as much. Amvuttra is now the third FDA-approved therapy for ATTR-CM, following Pfizers Vyndaqel and BridgeBios Attruby/Beyonttra.
Open Heart
MARCH 28, 2025
Aims Mavacamten, the first approved myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), addresses hypercontractility and left ventricular outflow tract (LVOT) obstruction. This study evaluates real-world experience with mavacamten, focusing on maintenance dose determination to optimise individual therapy and enhance patient safety.
Frontiers in Cardiovascular Medicine
MARCH 27, 2025
Observational studies and randomised controlled trials (RCTs) have yielded conflicting results regarding the outcomes of multiple arterial grafts (MAG) vs. single arterial grafts (SAG) in coronary artery bypass graft (CABG) surgery. We conducted a comprehensive search across multiple databases for RCTs that directly compared MAG and SAG. The clinical outcomes assessed included all-cause mortality, cardiac-specific mortality, myocardial infarction (MI), repeat revascularization, stroke, sternal w
Heart BMJ
MARCH 26, 2025
Advances in molecular genetics during the past decades led to seminal discoveries in the genetic basis of cardiovascular diseases, resulting in a new understanding of their pathogenesis, determinants of natural history and more recently paved the way for innovative therapies. A significant gap, however, exists between the rapidly increasing knowledge, especially of cardiovascular Mendelian disorders, and the medical applications in daily practice.
HCPLive
MARCH 27, 2025
Panelists discuss how biologic therapies for psoriasis are increasingly considered earlier in treatment algorithms based on the American Academy of Dermatology-National Psoriasis Foundation (AAD-NPF) Guidelines and updated International Psoriasis Council (IPC) severity classifications, with decisions influenced by disease extent, impact on quality of life, presence of psoriatic arthritis, treatment history, patient preferences, and the recognition that prompt intervention with biologics can prev
Nature Reviews - Cardiology
MARCH 27, 2025
Nature Reviews Cardiology, Published online: 28 March 2025; doi:10.1038/s41569-025-01147-w Countries globally face major challenges in the early diagnosis and treatment of hypercholesterolaemia and cardiovascular disease, with numerous health inequities by geography and income. Perseverance, hard work, integrity and commitment can transform aspiration into reality.
Open Heart
MARCH 28, 2025
Background Heart failure with preserved ejection fraction (HFpEF) is a complex clinical syndrome in which signs and symptoms of heart failure (HF) occur despite a normal left ventricular ejection fraction. Transthoracic echocardiography (TTE) is the first-line imaging modality but disparities in patient pathways across the UK can lead to delayed diagnosis and treatment.
Frontiers in Cardiovascular Medicine
MARCH 28, 2025
IntroductionVentricular septal defect (VSD) is a common congenital heart disease (CHD), accounting for 2030% of all CHD cases. While surgical closure has been the gold standard for treatment, transcatheter closure has emerged as a less invasive alternative, particularly for perimembranous VSDs. This study aimed to evaluate the early and mid-term outcomes of transcatheter closure using a double-disc occluder device in a single-center Vietnamese cohort.MethodA prospective descriptive study was con
Heart BMJ
MARCH 26, 2025
Pericardial complications are very common following cardiac surgery. It is estimated that up to 30–40% of patients may develop a postpericardiotomy syndrome (PPS) and >50–60% of patients show pericardial effusions after cardiac surgery. 1 2 Pericardial complications may range from asymptomatic pericardial and/or pleural effusion to cardiac tamponade, and may include PPS, and postoperative atrial fibrillation (POAF), triggered by pericarditis in predisposed individuals. 3 All thes
DAIC
MARCH 26, 2025
tim.hodson Wed, 03/26/2025 - 14:25 March 17, 2025 Bayer recently announcedthat the U.S. Food and Drug Administration (FDA) accepted its supplemental new drug application (sNDA) and granted Priority Review designation for KERENDIA(finerenone) for the treatment of adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).
Medical Xpress - Cardiology
MARCH 21, 2025
The coffee from most of the coffee machines in workplaces contains relatively high levels of cholesterol-elevating substances. There is a big difference in comparison to coffee made in regular paper filter coffee makers, which filter out most of these substances.
Open Heart
MARCH 22, 2025
Introduction Atrial fibrillation is the most prevalent sustained arrhythmia worldwide and is expected to increase substantially within the coming years. Although lifestyle changes and risk factor modification are now acknowledged as central components of atrial fibrillation management, the effects of exercise on disease-specific outcomes are still not extensively documented due to few high-quality randomised trials.
Frontiers in Cardiovascular Medicine
MARCH 25, 2025
ObjectivesNoise pollution has become an increasingly severe environmental issue in modern society and has been recognized for its adverse effects on cardiovascular diseases. Hypertension induced by noise exposure has garnered significant research interest and a large quantity of studies have been conducted. This study aims to employ bibliometric methods to comprehensively review the literature on the relationship between noise exposure and hypertension and to analyze the current state of researc
Cassling
MARCH 28, 2025
Founded in 1984, Casslings mission is to strengthen community healthcare. The company strives to bring innovative imaging solutions to communities and providers, so that patients and their families can live their best life. Thats why Cassling is excited to introduce a new awards program that recognizes and celebrates imaging teams contributions to keeping care local and improving patient outcomes.
DAIC
MARCH 27, 2025
tim.hodson Thu, 03/27/2025 - 15:40 March 27, 2025 GE HealthCare is announcing theU.S.launch of Flyrcado(flurpiridaz F 18) injection at the 2025American College of Cardiology(ACC) AnnualScientific Session & Expo inChicago. Flyrcado is aunit dose positron emission tomography myocardial perfusion imaging (PET MPI) agent. In 2024, the FDA approved Flyrcado for patients with known or suspected coronary artery disease (CAD), delivering higher diagnostic efficacy compared to single-photon emission com
Heart BMJ
MARCH 26, 2025
Heart failure (HF) is one of the significant complications in patients with myocardial infarction (MI), leading to increased risk for cardiovascular morbidity and mortality. 1 Left ventricular ejection fraction (LVEF) is a crucial parameter in HF assessment and management, although the differences in mortality are little different between HF with LVEF≥50% or HF with preserved ejection fraction (HFpEF) in patients with post-MI compared with HF with LVEF≤40% or HF with reduced ejection
Open Heart
MARCH 22, 2025
Introduction and objectives Decision-making regarding prognosticating out-of-hospital cardiac arrest (OHCA) remains challenging at the front door. The MIRACLE2 score provides a simple and practical tool for early neuroprognostication to aid decision-making. The study aims to validate the MIRACLE2 score in a district general hospital (DGH). Material and methods This is a retrospective analysis of the patients with OHCA and return of spontaneous circulation (ROSC) in the community who attended the
Frontiers in Cardiovascular Medicine
MARCH 25, 2025
Cardio-cerebral infarction (CCI) is a rare clinical syndrome characterized by the simultaneous or sequential occurrence of acute myocardial infarction (AMI) and acute ischemic stroke (AIS). Despite its complex pathogenesis and more severe prognosis compared to isolated AMI or AIS, no consensus has been established regarding its definition, classification, epidemiology, treatment protocols, or prognostic management.
International Journal of Cardiovascular Sciences
MARCH 27, 2025
The International Journal of Cardiovascular Sciences has extended the deadline for article submissions to the special issue on Artificial Intelligence in Cardiovascular Health until August 30, 2025 ! Publications in this collection will continue until December 2025. Brazilian and international researchers are invited to submit their work for this special issue, edited by Drs.
HeartRhythm
MARCH 28, 2025
Chronic ventricular pacing (VP) in the Fontan population is associated with adverse outcomes. Two studies evaluated risk factors for adverse outcomes related to VP. Chubb etal1 reported risk factors for a primary end point of death or transplant attributable to VP in an international multicenter, retrospective, case-control study. They compared 213 patients after Fontan with VP with matched controls and found a 4.6 times higher risk of the primary end point in the VP cohort, occurring in 22% at
Heart BMJ
MARCH 26, 2025
Background Atrial fibrillation (AF) is a major and increasing burden on health services. This study aimed to evaluate the cost-effectiveness of digoxin versus beta-blockers for heart rate control in patients with permanent AF and symptoms of heart failure. Methods RAte control Therapy Evaluation in permanent Atrial Fibrillation (RATE-AF) was a randomised, open-label, blinded, endpoint trial embedded in the UK National Health Service (NHS) to directly compare low-dose digoxin with beta-blockers (
Open Heart
MARCH 25, 2025
Background Cardiovascular disease (CVD) events triggered by inflammation are an underappreciated and poorly quantified cause of morbidity and mortality in patients with bloodstream infections (BSIs). We aimed to determine the risk of myocardial infarction (MI) and stroke after BSI. Methods This self-controlled case series study was conducted within the Secure Anonymised Information Linkage Databank, containing anonymised population-scale electronic health record data for Wales, UK.
Expert insights. Personalized for you.
71 
Let's personalize your content